172 related articles for article (PubMed ID: 22562177)
1. Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer.
Alshareeda AT; Rakha EA; Nolan CC; Ellis IO; Green AR
Breast Cancer Res Treat; 2012 Jul; 134(2):519-29. PubMed ID: 22562177
[TBL] [Abstract][Full Text] [Related]
2. A fatty acid-binding protein 7/RXRβ pathway enhances survival and proliferation in triple-negative breast cancer.
Liu RZ; Graham K; Glubrecht DD; Lai R; Mackey JR; Godbout R
J Pathol; 2012 Nov; 228(3):310-21. PubMed ID: 22322885
[TBL] [Abstract][Full Text] [Related]
3. The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer.
Zhang H; Rakha EA; Ball GR; Spiteri I; Aleskandarany M; Paish EC; Powe DG; Macmillan RD; Caldas C; Ellis IO; Green AR
Breast Cancer Res Treat; 2010 May; 121(1):41-51. PubMed ID: 19590950
[TBL] [Abstract][Full Text] [Related]
4. The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells.
Slipicevic A; Jørgensen K; Skrede M; Rosnes AK; Trøen G; Davidson B; Flørenes VA
BMC Cancer; 2008 Sep; 8():276. PubMed ID: 18826602
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
6. FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast.
Gromov P; Espinoza JA; Talman ML; Honma N; Kroman N; Timmermans Wielenga V; Moreira JM; Gromova I
PLoS One; 2014; 9(11):e112024. PubMed ID: 25389781
[TBL] [Abstract][Full Text] [Related]
7. Expression of BRCA1 protein in breast cancer and its prognostic significance.
Rakha EA; El-Sheikh SE; Kandil MA; El-Sayed ME; Green AR; Ellis IO
Hum Pathol; 2008 Jun; 39(6):857-65. PubMed ID: 18400253
[TBL] [Abstract][Full Text] [Related]
8. FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status.
Kaloshi G; Mokhtari K; Carpentier C; Taillibert S; Lejeune J; Marie Y; Delattre JY; Godbout R; Sanson M
J Neurooncol; 2007 Sep; 84(3):245-8. PubMed ID: 17415524
[TBL] [Abstract][Full Text] [Related]
9. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of nuclear hepatoma-derived growth factor (HDGF) localization in patients with breast cancer.
Chen X; Yun J; Fei F; Yi J; Tian R; Li S; Gan X
Pathol Res Pract; 2012 Aug; 208(8):437-43. PubMed ID: 22682760
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid binding protein 7 as a marker of glioma stem cells.
Morihiro Y; Yasumoto Y; Vaidyan LK; Sadahiro H; Uchida T; Inamura A; Sharifi K; Ideguchi M; Nomura S; Tokuda N; Kashiwabara S; Ishii A; Ikeda E; Owada Y; Suzuki M
Pathol Int; 2013 Nov; 63(11):546-53. PubMed ID: 24274717
[TBL] [Abstract][Full Text] [Related]
13. Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients.
Maciejczyk A; Łacko A; Ekiert M; Jagoda E; Wysocka T; Matkowski R; Hałoń A; Györffy B; Lage H; Surowiak P
Histol Histopathol; 2013 Apr; 28(4):513-24. PubMed ID: 23364898
[TBL] [Abstract][Full Text] [Related]
14. High nuclear MSK1 is associated with longer survival in breast cancer patients.
Pu X; Storr SJ; Ahmad NS; Rakha EA; Green AR; Ellis IO; Martin SG
J Cancer Res Clin Oncol; 2018 Mar; 144(3):509-517. PubMed ID: 29327245
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients.
Mirza S; Rakha EA; Alshareeda A; Mohibi S; Zhao X; Katafiasz BJ; Wang J; Gurumurthy CB; Bele A; Ellis IO; Green AR; Band H; Band V
Breast Cancer Res Treat; 2013 Feb; 137(3):721-31. PubMed ID: 23288344
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response.
Al-Kaabi MM; Alshareeda AT; Jerjees DA; Muftah AA; Green AR; Alsubhi NH; Nolan CC; Chan S; Cornford E; Madhusudan S; Ellis IO; Rakha EA
Br J Cancer; 2015 Mar; 112(5):901-11. PubMed ID: 25688741
[TBL] [Abstract][Full Text] [Related]
17. Y-box-binding protein 1 (YB1) in breast carcinomas: relation to aggressive tumor phenotype and identification of patients at high risk for relapse.
Mylona E; Melissaris S; Giannopoulou I; Theohari I; Papadimitriou C; Keramopoulos A; Nakopoulou L
Eur J Surg Oncol; 2014 Mar; 40(3):289-96. PubMed ID: 24075827
[TBL] [Abstract][Full Text] [Related]
18. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
[TBL] [Abstract][Full Text] [Related]
19. Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival.
Slipicevic A; Holm R; Emilsen E; Ree Rosnes AK; Welch DR; Mælandsmo GM; Flørenes VA
BMC Cancer; 2012 Feb; 12():73. PubMed ID: 22356677
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer.
Abduljabbar R; Negm OH; Lai CF; Jerjees DA; Al-Kaabi M; Hamed MR; Tighe PJ; Buluwela L; Mukherjee A; Green AR; Ali S; Rakha EA; Ellis IO
Breast Cancer Res Treat; 2015 Apr; 150(2):335-46. PubMed ID: 25762479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
